ArticleCurrent microbiology2026
In Vitro Antimicrobial Activities of Carbapenem-beta Lactamase Inhibitor Combinations Against Carbapenem-resistant Gram-negative Pathogens Isolated from Türkiye.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting KPC-ProducingMicroorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The global incidence of carbapenem resistance is increasing due to the presence of beta-lactamases such as carbapenemases. This study evaluated the in vitro antimicrobial activities and metabolic activities of biofilm cells of two carbapenem beta-lactamase inhibitor combinations, imipenem-cilastatin+relebactam and meropenem+vaborbactam, against imipenem and/or meropenem resistant, metallo-beta-lactamase negative clinical isolates of Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. Both combinations demonstrated antibacterial activity, particularly against P. aeruginosa and E. coli. MBCs were found higher than MICs against all microorganisms. Imipenem-cilastatin+relebactam was the most effective agent against K. pneumoniae and Enterobacter spp. biofilms, while meropenem-vaborbactam showed greater activity against P. aeruginosa, A. baumannii, and E. coli biofilms. This study presents new results by characterizing the antibiofilm activity of these combinations for the first time in clinical isolates from Türkiye. Synergy with colistin was observed in selected isolates, and no antagonist effect was detected in any of the strains studied. Therefore, the study results suggest that imipenem-cilastatin+relebactam and meropenem+vaborbactam combinations, alone or in combination with colistin, could play an important role in the treatment of carbapenem-resistant Gram-negative bacteria, including biofilm-associated diseases.
Indexed as
Identifiers
41721895What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.